Novaliq Clears the Obstacles in Ocular Track Delivery

Bernhard Gunther, CEO for Novaliq GmbH, introduces their approach to improving topical ocular track delivery. Detailing the challenges involved, Bernhard expands on their unique opportunity to resolve these issues by dissolving poorly soluble tracks, with low viscosity and surface tension.


Bernhard Günther

Bernhard Günther

Bernhard Günther joined Novaliq as CEO in January 2007. He has more than 20 years of experience in the field of ocular biopharmaceutics and medical devices.

View Full Profile